Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 6/20 | 1.00 |
| ▸ | AR | P10275 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | NR3C1 | P04150 | 9/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.75 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flumethasone SCHEMBL4555 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL3167856 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL13046613 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL11123357 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL11844543 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL10422222 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL11911307 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL4046 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL3167846 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT | |
| Flumethasone SCHEMBL20169795 | 1.00 | CYP3A4 (1.00) | CYP3A4PGRARHIF1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954265-B2 | Structures and mechanism for the design of highly potent glucocorticoids | VAN ANDEL RESEARCH INSTITUTE (US) | 2021-03-23 | — | — | US | disclosed |
| US-20190263853-A1 | STRUCTURES AND MECHANISM FOR THE DESIGN OF HIGHLY POTENT GLUCOCORTICOIDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-29 | — | — | US | disclosed |
| US-9975918-B2 | Highly potent glucocorticoids | VAN ANDEL RESEARCH INSTITUTE (US) | 2018-05-22 | — | — | US | disclosed |
| WO-2018071736-A1 | STRUCTURES AND MECHANISM FOR THE DESIGN OF HIGHLY POTENT GLUCOCORTICOIDS | VAN ANDEL RESEARCH INSTITUTE (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20170114088-A1 | PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2017-04-27 | — | — | US | disclosed |
| US-20170114088-A1 | PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS | TARO PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2017-04-27 | — | — | US | disclosed |
| US-20160251393-A1 | Highly Potent Glucocorticoids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| US-20160251393-A1 | Highly Potent Glucocorticoids | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| US-9428540-B2 | Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents | CLAVIS PHARMA ASA (NO) | 2016-08-30 | — | — | US | disclosed |
| US-9428540-B2 | Fatty acid esters of glucocorticoids as anti-inflammatory and anti-cancer agents | CLAVIS PHARMA ASA (NO) | 2016-08-30 | — | — | US | disclosed |
| US-20070297989-A1 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES | BIGGADIKE KEITH | 2007-12-27 | — | — | US | disclosed |
| US-20070297989-A1 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES | BIGGADIKE KEITH | 2007-12-27 | — | — | US | disclosed |
| US-7291608-B2 | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α | GLAXO GROUP LIMITED (US) | 2007-11-06 | — | — | US | disclosed |
| US-7291608-B2 | Anti-inflammatory 17.β.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.α | GLAXO GROUP LIMITED (US) | 2007-11-06 | — | — | US | disclosed |
| US-7288536-B2 | Specific glucocorticosteroid compound having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2007-10-30 | — | — | US | disclosed |
| US-7288536-B2 | Specific glucocorticosteroid compound having anti-inflammatory activity | GLAXO GROUP LIMITED (GB) | 2007-10-30 | — | — | US | disclosed |
| US-7208613-B2 | Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-04-24 | — | — | US | disclosed |
| US-7208613-B2 | Synthesis of s-fluoromethyl 6α,9α-difluoro-11β-hydroxy-16α-methyl-17α-propionyloxy-3-oxoandrosta-1,4-diene-17β-carbothioate | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2007-04-24 | — | — | US | disclosed |
| US-20070027128-A1 | Novel Anti-inflammatory Androstane Derivative | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
| US-20070027128-A1 | Novel Anti-inflammatory Androstane Derivative | GLAXO GROUP LIMITED (GB) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114088-A1 | PROCESS FOR THE PREPARATION OF 17-DESOXY-CORTICOSTEROIDS | CYP17A1, HSD17B7, HSD17B2 | CYP3A4 55/4885PGR 620/4885AR 205/4885 |
| US-20160251393-A1 | Highly Potent Glucocorticoids | NR3C1, NR3C2, MC2R | CYP3A4 384/4885PGR 184/4885AR 60/4885 |
| US-20070297989-A1 | NOVEL ANTI-INFLAMMATORY ANDROSTANE DERIVATIVES | NR5A1, HSD3B2, HSD3B1 | CYP3A4 231/4885PGR 165/4885AR 30/4885 |
| US-20070027128-A1 | Novel Anti-inflammatory Androstane Derivative | NR5A1, CYP17A1, HSD17B11 | CYP3A4 106/4885PGR 157/4885AR 41/4885 |
| US-20190263853-A1 | STRUCTURES AND MECHANISM FOR THE DESIGN OF HIGHLY POTENT GLUCOCORTICOIDS | NR3C1, NR3C2, MC2R | CYP3A4 209/4885PGR 99/4885AR 42/4885 |
| US-10954265-B2 | Structures and mechanism for the design of highly potent glucocorticoids | NR3C1, NR3C2, MC2R | CYP3A4 209/4885PGR 99/4885AR 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.